A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis

A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis (November 2020)

Friday, November 6, 2020
Webinar -- 6:00 PM ET


6:00 PM Welcome and Program Overview

6:15 PM Targeted DMARDs: An Evolving Landscape

6:45 PM Developing Patient-Centered Care Treatment Plans

7:10 PM Question and Answer Session

7:30 PM Adjournment

*Attendees must be registered for the ACR Convergence 2020 to participate.

This is not an official program of the American College of Rheumatology.



Stanley B. Cohen, MD

Clinical Professor 
Department of Internal Medicine
University of Texas Southwestern Medical School
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Sheetal Desai, MD, MSEd

Chief of Rheumatology, Interim
Rheumatology Fellowship Program Director
Director, Lupus Clinic
Associate Clinical Professor of Medicine
Division of Rheumatology
University of California, Irvine
Irvine, California

Eric Ruderman, MD

Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Goal Statement
The goal of this activity is to improve clinician competence in considering the patient perspective and in applying efficacy and safety data from recent studies of new and emerging targeted DMARD therapies when considering treatment options for patients with active RA.

Target Audience
This activity is intended for rheumatology specialists and registered nurses attending ACR/ARP Annual Meeting as well as other healthcare providers who work in a rheumatology practice or treat patients with RA.

Learning Objectives
Upon completion of this activity, learners should be able to:

  • Engage patients in describing the range of their RA burden, their expectations of disease control with therapy, and their treatment preferences
  • Summarize key findings from the latest clinical trials of new and emerging targeted therapies for patients with active RA, including those who have who have failed other DMARDs
  • Detail JAK selectivity as it relates to current and emerging JAK inhibitor drugs and safety outcomes to date for individual agents


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.